ISABELLA BROWN: Open Payments
NPI 1720779689 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,378 in 117 payments from 28 companies in 2025. Trend: 2023 $32 · 2024 $1,067 · 2025 $2,378
Food & beverage: $2,378
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $380 |
| Vanda Pharmaceuticals Inc. | 10 | $289 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $219 |
| Ardelyx, Inc. | 9 | $191 |
| Janssen Biotech, Inc. | 9 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $170 |
| Regeneron Healthcare Solutions, Inc. | 7 | $143 |
| Madrigal Pharmaceuticals | 4 | $115 |
| Braintree Laboratories, Inc. | 3 | $81 |
| Lilly USA, LLC | 5 | $80 |
Products named: IBSRELA, DUPIXENT, TREMFYA, HETLIOZ, ENTYVIO, RINVOQ, XIFAXAN, REZDIFFRA.
Industry payments across KY — which companies pay providers there.
